Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).

被引：0
|
作者：
Ogata, Yutaka
Akagi, Yoshito
Kakeji, Yoshihiro
Emi, Yasunori
Oki, Eiji
Saeki, Hiroshi
Touyama, Tetsuo
Samura, Hironori
Baba, Hideo
Natsugoe, Shoji
Shirouzu, Kazuo
Tokunaga, Shoji
Maehara, Yoshihiko
机构：
[1] Kurume Univ, Dept Surg, Kurume Med Ctr, Sch Med, Kurume, Fukuoka, Japan
[2] Kurume Univ, Dept Surg, Sch Med, Kurume, Fukuoka, Japan
[3] Kyushu Univ, Dept Surg & Sci, Fukuoka, Japan
[4] Nakagami Hosp, Okinawa, Japan
[5] Univ Ryukyus, Dept Surg 1, Nishihara, Okinawa, Japan
[6] Kumamoto Univ, Dept Surg Gastroenterol, Kumamoto, Japan
[7] Kagashima Univ, Dept Gastrointestinal Surg, Kagoshima, Japan
[8] Kyushu Univ Hosp, Med Informat Ctr, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
602
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) plus /- Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
    Schwartzberg, L. S.
    Hermann, R.
    Blakely, J.
    Richey, S. S.
    Tauer, K. W.
    Childs, B. H.
    CANCER RESEARCH, 2010, 70
  • [42] Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study
    J Feliu
    A Salud
    P Escudero
    L López-Gómez
    C Pericay
    C Castañón
    M R López de Tejada
    J M Rodríguez-García
    M P Martínez
    M Sanz Martín
    J J Sánchez
    M González Barón
    British Journal of Cancer, 2004, 90 : 1502 - 1507
  • [43] Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)
    Nakayama, Goro
    Mitsuma, Ayako
    Sunagawa, Yuki
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Matsui, Takanori
    Nakayama, Hiroshi
    Nakata, Kazuhiko
    Ishiyama, Akiharu
    Asada, Takahiro
    Umeda, Shinichi
    Ezaka, Kazuhiro
    Hattori, Norifumi
    Takami, Hideki
    Kobayashi, Daisuke
    Tanaka, Chie
    Kanda, Mitsuro
    Yamada, Suguru
    Koike, Masahiko
    Fujiwara, Michitaka
    Fujii, Tsutomu
    Murotani, Kenta
    Ando, Yuichi
    Kodera, Yasuhiro
    ONCOLOGIST, 2018, 23 (08): : 919 - 927
  • [44] Modified FOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab beyond first progression in advanced colorectal cancer: CCOG-0801 study.
    Ishigure, Kiyoshi
    Nakayama, Goro
    Uehara, Keisuke
    Yokoyama, Hiroyuki
    Ishiyama, Akiharu
    Eguchi, Takehiko
    Tsuboi, Kenji
    Ando, Yuichi
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [45] Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
    Doi, Toshihiko
    Boku, Narikazu
    Kato, Ken
    Komatsu, Yoshito
    Yamaguchi, Kensei
    Muro, Kei
    Hamamoto, Yasuo
    Sato, Atsushi
    Koizumi, Wasaburo
    Mizunuma, Nobuyuki
    Takiuchi, Hiroya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 913 - 920
  • [46] PHASE II STUDY OF BEVACIZUMAB plus OXALIPLATIN PLUS CAPECITABINE FOLLOWED BY BEVACIZUMAB plus ERLOTINIB AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
    Munoz, A.
    Pericay, C.
    Llorente, B.
    Alonso, V
    Duenas, R.
    Roca, J.
    Rivera, F.
    Falco, E.
    Alvarez, I
    Salud, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 73 - 74
  • [47] Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
    Schmoll, Hans-Joachim
    Cunningham, David
    Sobrero, Alberto
    Karapetis, Christos S.
    Rougier, Philippe
    Koski, Sheryl L.
    Kocakova, Ilona
    Bondarenko, Igor
    Bodoky, Gyoergy
    Mainwaring, Paul
    Salazar, Ramon
    Barker, Peter
    Mookerjee, Bijoyesh
    Robertson, Jane
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3588 - 3595
  • [48] PRESPECIFIED SUBGROUP ANALYSES IN WJOG4407G TRIAL, A RANDOMIZED PHASE III TRIAL OF MFOLFOX6 PLUS BEVACIZUMAB VERSUS FOLFIRI PLUS BEVACIZUMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
    Hiroshi, Tamagawa
    Kentaro, Yamazaki
    Koichi, Suyama
    Michio, Okabe
    Kazuya, Suzuki
    Nobuhiko, Seki
    Kentaro, Kawakami
    Mikio, Sato
    Yasuo, Takahashi
    Tomonori, Hirashima
    Masahide, Ebi
    Keisei, Taku
    Toshio, Otsuji
    Fumio, Tamura
    Eiji, Shinozaki
    Koji, Nakashima
    Kensei, Yamaguchi
    Masahiko, Ando
    Satoshi, Morita
    Narikazu, Boku
    Ichinosuke, Hyodo
    ANNALS OF ONCOLOGY, 2014, 25
  • [49] MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumabas First-line Chemotherapy in Metastatic Colorectal Cancer
    Parikh, Aparna R.
    Lee, Fa-Chyi
    Yau, Linda
    Koh, Han
    Knost, James
    Mitchell, Edith P.
    Bosanac, Ivan
    Choong, Nicholas
    Scappaticci, Frank
    Mancao, Christoph
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2019, 25 (10) : 2988 - 2995
  • [50] FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
    Cremolini, C.
    Rossini, D.
    Antoniotti, C.
    Pietrantonio, F.
    Lonardi, S.
    Salvatore, L.
    Marmorino, F.
    Borelli, B.
    Ambrosini, M.
    Barsotti, G.
    Di Stefano, B.
    Masi, G.
    Boccaccino, A.
    Tamberi, S.
    Tamburini, E.
    Frassineti, L. G.
    Simionato, F.
    Fontanini, G.
    Boni, L.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1294 - S1295
12345